Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I am still in RDHL as it is in my Roth IRA - I cannot claim losses - so it is sitting there. I sold my major stake from trading account and booked losess
Are you still in it?
One of my big loss makers and disappointment - NNOX is another loss maker - thought it had big promise
BLIX - booked losses
I am quite curious, are you
still in RDHL, or have you
already sold out?
Israel to expand use of COVID drug that gets 88% of patients out of hospital
The Health Ministry has approved the expanded use of an innovative COVID-19 treatment that helped 14 out of 16 severe patients who took it to be released from the hospital one day after receiving their final dose.
https://flip.it/dpfOP_
Bonus BioGroup Ltd. (BONS.TA)
Tel Aviv - Tel Aviv Delayed Price. Currency in ILA
In watchlist
150.00+19.20 (+14.68%)
As of 11:34AM IDT. Market open.
3 Israeli Biotech Stocks Driving Global COVID-19 Innovation
https://www.investing.com/analysis/3-israeli-biotech-stocks-driving-global-covid19-innovation-200595385
By David KellerStock Markets
Aug 02, 2021 03:42AM ET
As it turns out, we’re not out of the woods yet in terms of the negative effects of the COVID-19 pandemic on the global economy. Last Monday, Goldman Sachs lowered its projections for US economic growth over Q3 and Q4 in response to mounting anxiety over stagnating consumer spending alongside the rapid spread of the Delta variant.
These lowered expectations for the US, and by extension worldwide economic recovery, coincides with surging infection rates across the world.
This correlation should not be simply shrugged off; the tight nexus between global infection rates and economic performance has been clearly illustrated since the outbreak of the pandemic in early 2020 and the corresponding downturn in stock exchanges worldwide witnessed in March 2020.
With the roll-out of vaccines, the global economy has since enjoyed a bullish rally over Q1 and Q2 2021, engendering high hopes of a robust, K-shaped recovery. Yet, as the Dow Jones, S&P 500, and NASDAQ composite indexes rose to new all-time highs in July 2021, an increasingly vocal chorus of analysts and investors are bracing themselves for another COVID-induced market correction in coming months.
Despite the successful race-to-the-finish for an effective and safe vaccine, spearheaded by pharmaceutical giants such as Pfizer (NYSE:PFE), Moderna (NASDAQ:MRNA), and Johnson & Johnson (NYSE:JNJ), a myriad of public health challenges remain that continue to impact a broader macroeconomic recovery.
These outstanding difficulties range from starkly uneven vaccination rates from country-to-country, to vaccine hesitancy, to new, more potent, strains’ ability to infect the fully inoculated. In response, a number of biotechnology and pharmaceutical innovators are stepping up to the plate in exploring novel COVID-19 therapies and solutions.
Israel has long been recognized as a hub of inventive biotechnology and life-sciences firms, living up to its reputation as the start-up capital of the world. Dozens of companies that originated in Israel or on the Tel Aviv Stock Exchange (TASE) have successfully listed on major American indices, such as NASDAQ and the NYSE.
In fact, the Israeli life sciences sector raised record funds in 2020, representing a 55% year-on-year increase that is only expected to continue moving forward. This set of favorable market and domestic conditions has led several Israeli biotech and pharma companies to initiate intensive R&D efforts to bring a wider portfolio of COVID-19 solutions, from orally-ingested vaccines to regenerative cell-therapies, to market.
A survey of three of these Israeli biotech disruptors can shed light on emerging treatments that, as outlined above, are liable to exert a significant impact on both share price and overall market performance.
1. Bonus BioGroup
Bonus Biogroup (TASE:BONS) is an Israel-based innovator that is working to apply cell therapy and regenerative medicine to the treatment of severe COVID-19 cases. On July 19, Bonus reported further improvements in key parameters tested in Phase I/II clinical trials for its MesenCure treatment.
Bonus’ newfangled MesenCure relies on activated mesenchymal stromal (stem) cells taken from healthy adult donors. Using these stem cells, MesenCure works to reduce severe COVID-related symptoms such as acute pneumonia and organ failure that are caused by a massive inflammatory reaction (viz. Cytokine storm) in patients suffering from severe COVID.
Given MesenCure’s measured 100% success rate to-date, the Israeli Ministry of Health has approved the continuation of Phase II clinical trials, set to take place at Haifa’s Rambam Medical Center.
2. Oramed Pharmaceuticals
On July 22, Oramed Pharmaceuticals Inc (NASDAQ:ORMP) announced that it is beginning clinical trials in Israel for a prospective single-dose, oral vaccine currently being developed by India-based Premas Biotech.
A single-dose orally administered vaccine has massive potential to close the gap in vaccination rates between developed and developing countries. India is a prime example, where a mere 5% of the population is vaccinated, and issues in logistics and supply have severely hampered an effective vaccine rollout. Pending final approval from the Israeli Ministry of Health, Oramed is expecting to begin the trials next month at Tel Aviv’s Sourasky Medical Center.
3. RedHill Biopharma
Another Israeli company energetically pursuing orally-administered COVID treatments is Redhill Biopharma Ltd (NASDAQ:RDHL). RedHill approaches the puzzle of novel COVID treatments from its area of expertise as a specialty pharmaceutical company. On July 19, the company announced its had completed patient-follow-up in a 475-participant global Phase II/III study of an oral treatment for severe COVID-19.
RedHill’s solution is based on Opaganib, a proprietary chemical entity with antiviral and anti-inflammatory properties that can be orally administered for the treatment of severe cases of COVID-19 and its emerging, more aggressive, strains. While further results are expected in coming weeks and the company has yet to receive regulatory approval for general use, RedHill’s development of a potentially revolutionary chemical entity, Opaganib, points to the creative direction Israeli R&D is taking in response to the ongoing pandemic.
YTD ChartsYTD Charts
These three biotech and pharma companies are a representative sample of some of the pioneering solutions for SARS-CoV-2 viruses being explored in Israel and beyond.
Not only do these examples showcase the accelerated scientific innovation spurred by the pandemic, but they also typify the agility and adaptability of private sector actors in responding to fast-changing circumstances.
The world was awed by the relative speed in which leading pharmaceutical companies such as Pfizer and Moderna developed an effective COVID-19 vaccine; as the virus morphs and persists, other actors like Oramed, RedHill, and Bonus BioGroup are now leading the charge in developing life-saving treatments.
As markets brace for a potential pullback in Q4, enormous potential remains to be capitalized on in the biotech and pharma sectors, specifically with respect to COVID solutions. The rise or fall of biotech stocks is notoriously dependent on external variables such as the outcome of clinical trials and regulatory approvals, thus demanding a high level of scrutiny from investors.
Even so, the unmatched urgency for a wider portfolio of global COVID treatments has opened up a number of highly-lucrative investment opportunities. Israel’s robust biopharma sector is a veritable goldmine of pending COVID-19 treatments and therapies that are waiting to be tapped by the discerning and forward-thinking investor.
Bonus Biogroup Ltd ( (BBIXF)
0.44 ? 0.03 (7.32%)
Volume: 14,900 @07/21/21 3:13:59 PM ED
Indeed, getting noticed!
Volume 103,200
Huh, with a measly 1-2k average trading day
volume, now already 103k? Is the company
finally being noticed?
Bonus BioGroup Reports Resounding Success in Phase-I Clinical Trials for Regenerative COVID-19 Treatment
https://finance.yahoo.com/news/bonus-biogroup-reports-resounding-success-001500313.html
TEL AVIV, ISRAEL / ACCESSWIRE / July 19, 2021 / Bonus BioGroup LTD (TASE:BONS), an Israeli clinical-stage biotechnology company, announced further improvements in key parameters measured in phase I/II Clinical Trials for its advanced cell therapy product, MesenCure. The latest report follows Bonus BioGroup's May 27th announcement of MesenCure'scomplete success in the treatment of severe COVID-19 patients suffering from life-threatening pneumonia and acute respiratory distress. These new findings emerge against the backdrop of the rapid spread of new SARS-CoV-2 variants, a decrease in vaccine effectiveness, and a rise in infection rates worldwide.
The latest round of results revealed an improvement in parameters associated with patient prognosis, recovery, and chance of survival. More specifically, Bonus BioGroup noted a reduced risk of multiorgan dysfunction, heart/kidney injuries, and venous thromboembolism (VTE) in COVID patients after the first dose of MesenCure, with a cumulative effect observed when multiple doses were administered.
These findings were obtained after the Company completed an additional analysis of the results it obtained in a Phase I/II clinical trial held at the Rambam Health Care Campus in Haifa, Israel that was geared towards evaluating the safety and efficacy of MesenCure in the treatment of severe COVID-19 patients. In such cases, inflammation and tissue damage are detected not only in the lungs, but also in the heart and the kidneys at levels more than ten times higher than those observed in milder patients.
For more information visit https://www.bonusbiogroup.com
Among the severe COVID-19 cases treated with the MesenCure,90% of the patients suffered from pre-existing conditions that increase the risk of severe illness and complications and carry a mortality rate of over 35%. Following treatment, these patients' saw significant improvements in overall respiratory function and a rapid reduction in the area of diffuse lung inflammation. In addition to objective indices measured in the trial, patients treated with MesenCure reported notable improvements in subjective parameters used to assess general health including mobility, capacity for self-care, ability to perform routine actions, degree of pain, and anxiety.
These promising results were reinforced by Dr. ShadiHamoud, Head of the Research Unit and Deputy Director of the Department of Internal Medicine at Rambam Medical Campus, who stated: "The treatment results of MesenCure are thus far very impressive, and are significantly better compared to those achieved with other therapies. All patients treated with MesenCurewere in a severe condition and suffered from acute respiratory distress, diffuse pneumonia (as perchest radiograph), and blood parameters indicative of a cytokine storm. Moreover, about 90% of the trial participants suffered from comorbidities known as risk factors for increased disease severity, complications, and mortality."
"If not for MesenCure, the patients' prognosis was poor, with low chances of recovery and survival. However, thanks to the treatment with BonusBioGroup's MesenCure, the patients have shown significant improvements in tested parameters and were released from the hospital only one day (per median calculation) following the treatment conclusion. Thus, the treatment withMesenCure showed good and surprising results that generated significant interest within other hospital departments. We hope to treat a large number of patients with this cell therapy method, and we will strive to extend its use to other applications as well."
The effectiveness displayed by MesenCure derives from Bonus BioGroup's enhancement of the mesenchymal cells that make up the drug via a unique combination of biological and physical growth conditions while shortening the cells' total growth period that improves the treatment's safety. As a consequence of the excellent outcomes witnessed in the phase I/II clinical trial, the Israel Ministry of health (IMOH) approved continuation to a Phase IItrials. This will include up to 50 additional severeCOVID-19 patients, and will be conducted at Rambam Health Care Campus under the supervision of Dr. Shadi Hamoud, the primary investigator in the Phase I/II trial.
About Bonus BioGroup
Since its establishment, Bonus BioGroup has worked to develop cell therapies and tissue-engineered products for bone regeneration. The main component of the viable bone graft developed by the Company are mesenchymal stromal cells isolated from the patient's adipose tissue. During the outbreak of the COVID-19 pandemic, the Company started to study these mesenchymal cells and their potential applications to attenuating the associated hyper-inflammatory response (i.e., cytokine storm) provoked by COVID-19 and other diseases. In the development of MesenCure, Bonus BioGroup applied a variety of unique technologies and proprietary knowledge, some of which are currently in development by the Company, and some of which are part of the Company's broad intellectual property portfolio, which includes fourteen approved patents and eighteen patent applications in many countries around the globe.
Israeli biotech company aces Phase I Covid cure trial
Without being treated with new drug, patients had poor chance of recovery and survival. Following treatment, they were quickly discharged.
By Naama Barak MAY 31, 2021, 10:00 AM (NOTE: Not a new article)
Israeli biotech company Bonus BioGroup successfully completes its Phase I clinical trial for the treatment of Covid-19.
Israeli biotechnology company Bonus BioGroup recently announced positive preliminary results of its Phase I clinical trial for treating severely ill Covid-19 patients, perhaps bringing closer a cure for the coronavirus.
The trial involved treating 10 Covid patients aged 45 to 75 hospitalized at Rambam Health Care Campus in Haifa with MesenCure, Bonus BioGroup’s cell therapy drug candidate.
“All of the patients being treated with MesenCure were severe Covid patients whose illness was manifested in acute respiratory distress, in chest X-rays that showed diffused pneumonia and other blood indices that point to a cytokine storm,” explained Rambam’s Dr. Shadi Hamoud, the lead researcher in the trial.
“In addition, 90 percent of the participants in this clinical trial also suffered from background diseases known as risk factors for serious illness, complications and death,” he said.
“Without being treated with the MesenCure drug, the prognosis of these patients was a poor chance of recovery and low chance of survival. However, thanks to treatment with MesenCure from Bonus BioGroup, the patients exhibited significant improvements in the parameters tested,” he adds.
After the treatment, they spent one day in outpatient care before being discharged.
Following the trial’s success, the Israeli Health Ministry has approved transition to Phase II, which will include an additional 50 coronavirus patients.
MesenCure consists of activated mesenchymal stromal (stem) cells from healthy adult donors. The activation of these MSCs is intended to boost their ability to reduce lung inflammation, promote regeneration of the diseased lung tissue, and alleviate respiratory and other symptoms in the lungs.
The drug, intended to treat life-threatening respiratory distress, could also possibly be used to treat other diseases such as lower respiratory tract infections, chronic obstructive pulmonary disease and asthma.
Meanwhile, the EXO-CD24 experimental treatment for Covid-19, developed by Dr. Nadir Abir at Tel Aviv Sourasky Medical Center, also won approval from the Health Ministry to begin a Phase II/III trial. Several other countries may run trials as well.
Slowly but surely, some action:
Day's Range 0.3600 - 0.3900
52 Week Range 0.0900 - 0.5500
Volume 12,000
Avg. Volume 28,549
Sleeping beauty waking up?
Here you go:
Bonus Biogroup Ltd ( (BBIXF)
0.36 ^ 0.0057 (1.61%)
Volume: 7,000 @06/24/21 10:58:45 AM EDT
There was one trade:
https://investorshub.advfn.com/Bonus-BioGroup-Ltd-BBIXF-39658/
A measly 3k shares traded.
As said, much more active in TASE.
BTW have you looked into CLGN in its
latest news?
No trading possible - I put some order but not being executed for entire day
According to Yahoo:
Day's Range 0.4100 - 0.4100
52 Week Range 0.0900 - 0.5500
Volume 41,100
Avg. Volume 28,947
https://finance.yahoo.com/quote/BBIXF?p=BBIXF
In previous days trading was pitifully low,
in TASE, however, BONS.TA is quite lively
even on non news day.
https://www.google.com/search?q=BONS.TA&oq=bons.&aqs=chrome.1.69i57j69i59j0j46i175i199j46i10j0i10l2j0l2.7342j0j4&sourceid=chrome&ie=UTF-8
https://finance.yahoo.com/quote/BONS.TA/
Volume 45,900
Avg. Volume 29,182
WOW, almost twice average volume
ans still 2 hours to go till EOD!
Yes I remember my prediction on ORMP - it proved me wrong but I am happy as I have ok position and 100%+ profit but could not build more position that I intended to do
A much more active stock in TASE:
https://www.tase.co.il/en/market_data/security/485011/major_data
I already started position
Agree with many of your points
This is great news but this is not their main area - this may give the co visibility due to Covid but bone regeneration is the magic.
This may be a good company but not good investment as we may have to wait for years
Thanks Midas for creating the mb
The company is more like science fiction - none regeneration from from fat tissue - in 2 weeks solid bone being generated in the bone gap - one cannot believe it. They have been trying it from 2016
So it is very speculative or gambling investment if one does it. Too good to be true - same as NNOX
10 serious COVID patients given Israeli drug, leave hospital in one day
The data showed a 40% decrease in lung inflammation from treatment – from 55% to 15%, as seen in chest X-rays * Rambam Health Care Campus doctor: ‘Results extremely impressive’
https://www.jpost.com/health-science/10-serious-covid-patients-given-israeli-drug-leave-hospital-in-one-day-669564
By MAAYAN JAFFE-HOFFMAN MAY 29, 2021 22:39
An Israeli biotechnology company has claimed a 100% success rate in the first 10 patients treated with its drug as part of an early-stage clinical trial at Rambam Health Care Campus in Haifa.
The company, Bonus BioGroup, presented the preliminary findings of its Phase I/II trial to peers at the International Society for Cell & Gene Therapy conference in New Orleans last week and shared the results in a statement released to the Tel Aviv Stock Exchange.
The Jerusalem Post, which first wrote about the treatment in May 2020, reviewed the PowerPoint presented at the conference and the five-page letter sent to the exchange. The company’s CEO and director, Dr. Shai Meretzki, told the Post that the team is now working on publishing its results in a peer-reviewed journal.
Bonus’s MesenCure, which consists of activated Mesenchymal Stromal Cells (MSCs) that are isolated from the adipose tissue of healthy donors, was found to reduce inflammation and alleviate respiratory and other symptoms in patients suffering from life-threatening respiratory distress brought on by COVID-19.
“So far, the results of the treatment with the drug MesenCure are extremely impressive and an improvement over the results of other treatments,” said Dr. Shadi Hamoud, principal investigator in the clinical trial and deputy director of the Department of Internal Medicine E at Rambam.
He said the results were so promising that the hospital was already examining use of the treatment for other indications.
Bonus reported on 10 COVID patients between the ages of 45 to 75, all with severe symptoms. Ninety percent of them also had comorbidities.
The data showed a 40% decrease in lung inflammation from treatment – from 55% to 15%, as seen in chest X-rays, in the first five days after treatment. One month later, lung inflammation reached 1%.
Additionally, patients showed significantly improved respiratory function, with blood oxygen saturation increasing to 95% and lung functioning returning to almost entirely normal levels after only one month.
Meretzki shared a laboratory image of a healthy lung, a sick lung and lung treated with MesenCure. “The treated lung looks almost identical to the normal, healthy lung – complete healing, complete prevention of damage to the lung,” Meretzki said.
Most strikingly, patients were discharged from the hospital after a median duration of only one day following the treatment.
And there were no adverse effects associated with MesenCure, the company reported.
Meretzki said the trial followed patients for 30 days post administration of the treatment. All but one had survived. The patient who died did not pass away from COVID-19 but a severe preexisting condition.
Many COVID-19 patients die because of an increase in the production of inflammatory molecules called cytokine, rather than the virus itself, Meretzki explained. When the immune system secretes too many cytokines, a so-called “cytokine storm” can erupt. Such an excessive immune response ravages healthy lung tissue, leading to acute respiratory distress syndrome or failure, and eventually death.
Bonus was founded in 2008. It has been working with MSCs for a decade from its Haifa headquarters, where it developed its core product, a tissue-engineered bone graft that is also based on MSCs.
Meretzki said that MSCs are cells that are “found in every one of us; they are responsible for damage control and a variety of day-to-day activities.”
When the coronavirus outbreak started in early 2020, Bonus started investigating the potential of MSCs to possibly reduce the cytokine storm in COVID-19 patients.
The Phase II trial is slated to continue at Rambam and include another 50 patients. However, because of the low-level of infection in Israel, Bonus has applied for approval to carry out the trial in Europe as well, Meretzki said.
He told the Post that the Phase II trial should be completed quickly once the remaining patients are fully enrolled.
Followers
|
1
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
76
|
Created
|
06/09/21
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |